Benjamin Jackson CFA
Stock Analyst at Jefferies
(3.11)
# 2,543
Out of 4,574 analysts
88
Total ratings
52.2%
Success rate
5.5%
Average return
Main Sectors:
Stocks Rated by Benjamin Jackson CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: GALD Galderma Group AG | Maintained: Buy | CHF 205.00 | CHF 173.65 | +18.05% | 33 | Jul 23, 2026 | |
| ZLDPF Zealand Pharma A/S | Downgraded: Hold | $77 → $49 | $45.01 | +8.13% | 3 | Jul 13, 2026 | |
| LON: 0MGB Genmab A/S | Maintained: Buy | kr 2,650 → kr 2,800 | kr 1,877 | +49.14% | 2 | Jul 8, 2026 | |
| LON: 0DPB Bavarian Nordic A/S | Maintained: Buy | kr 275.00 → kr 280.00 | kr 174.30 | +60.64% | 2 | May 19, 2026 | |
| EPA: IPN Ipsen S.A. | Maintained: Hold | €117.00 | €158.40 | -26.14% | 2 | May 17, 2026 | |
| SWX: COPN Cosmo N.V. | Maintained: Buy | CHF 150.00 → CHF 140.00 | CHF 63.60 | +120.13% | 2 | Mar 25, 2026 | |
| GMAB Genmab | Initiated Coverage: Buy | $42 | $28.87 | +43.75% | 1 | Feb 17, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 110.00 | CHF 126.90 | -13.32% | 5 | Feb 4, 2026 | |
| EPA: SAN Sanofi | Maintained: Buy | €100.00 | €76.03 | +31.53% | 9 | Dec 29, 2025 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Sell | kr 415.00 → kr 290.00 | kr 320.60 | -9.54% | 7 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | CHF 270.00 → CHF 230.00 | CHF 355.10 | -35.23% | 6 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | 1,450p | 1,920p | -24.46% | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | 10,900p | 12,670p | -13.97% | 2 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $28 | $37.92 | n/a | 1 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €6.80 | €3.45 | n/a | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3.8 | $1.94 | n/a | 1 | Oct 7, 2024 |
Galderma Group AG
Jul 23, 2026
Maintained: Buy
Price Target: CHF 205.00
Current: CHF 173.65
Upside: +18.05%
Zealand Pharma A/S
Jul 13, 2026
Downgraded: Hold
Price Target: $77 → $49
Current: $45.01
Upside: +8.13%
Genmab A/S
Jul 8, 2026
Maintained: Buy
Price Target: kr 2,650 → kr 2,800
Current: kr 1,877
Upside: +49.14%
Bavarian Nordic A/S
May 19, 2026
Maintained: Buy
Price Target: kr 275.00 → kr 280.00
Current: kr 174.30
Upside: +60.64%
Ipsen S.A.
May 17, 2026
Maintained: Hold
Price Target: €117.00
Current: €158.40
Upside: -26.14%
Cosmo N.V.
Mar 25, 2026
Maintained: Buy
Price Target: CHF 150.00 → CHF 140.00
Current: CHF 63.60
Upside: +120.13%
Genmab
Feb 17, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $28.87
Upside: +43.75%
Novartis AG
Feb 4, 2026
Maintained: Hold
Price Target: CHF 110.00
Current: CHF 126.90
Upside: -13.32%
Sanofi
Dec 29, 2025
Maintained: Buy
Price Target: €100.00
Current: €76.03
Upside: +31.53%
Novo Nordisk A/S
Oct 27, 2025
Maintained: Sell
Price Target: kr 415.00 → kr 290.00
Current: kr 320.60
Upside: -9.54%
Oct 27, 2025
Downgraded: Sell
Price Target: CHF 270.00 → CHF 230.00
Current: CHF 355.10
Upside: -35.23%
Jul 30, 2025
Maintained: Hold
Price Target: 1,450p
Current: 1,920p
Upside: -24.46%
Jul 29, 2025
Maintained: Hold
Price Target: 10,900p
Current: 12,670p
Upside: -13.97%
Jan 31, 2025
Upgraded: Buy
Price Target: $28
Current: $37.92
Upside: n/a
Nov 13, 2024
Maintained: Hold
Price Target: €6.80
Current: €3.45
Upside: n/a
Oct 7, 2024
Downgraded: Hold
Price Target: $3.8
Current: $1.94
Upside: n/a